Related by context. Frequent words. (Click for all words.) 68 excessive sleepiness 64 diabetic neuropathic pain 63 ramelteon 63 RLS symptoms 62 chronic insomnia 61 insomnia 61 vasomotor symptoms 60 menstrual pain 60 GERD symptoms 59 SILENOR TM 59 systemic lupus erythematosus SLE 58 syndrome RLS 58 dysmenorrhea 58 fibromyalgia syndrome 58 neuropsychiatric symptoms 58 carcinoid syndrome 58 doxepin 57 dyskinesias 57 daytime sleepiness 57 lupus nephritis 57 perennial allergic rhinitis 57 excessive daytime sleepiness 57 mixed dyslipidemia 56 placebo controlled clinical 56 pramlintide 56 Major Depressive Disorder 56 atopic eczema 56 attention-deficit/hyperactivity disorder ADHD 56 gastrointestinal symptoms 56 Parkinson disease PD 56 MAP# 55 NUVIGIL 55 mirtazapine 55 heavy menstrual bleeding 55 cataplexy 55 hypoparathyroidism 55 acute migraine 55 ROZEREM 55 major depressive disorder 55 zileuton 55 infantile spasms 55 sleep disorders 55 double blinded placebo 55 allergic rhinitis 54 IBS symptoms 54 hyperactivity impulsivity 54 pramipexole 54 dose limiting toxicities 54 lacosamide 54 postherpetic neuralgia 54 aripiprazole 54 Restless Legs Syndrome 54 single ascending dose 54 bipolar depression 54 sleep disturbances 54 peripheral neuropathic pain 54 PRX # 54 hypocalcemia 54 rotigotine 54 CMV infection 54 blepharospasm 54 Topiramate 54 female sexual arousal 54 reflux disease 54 citalopram 54 hypercalcemia 54 hepatic encephalopathy 54 ADHD symptoms 54 depressive symptoms 53 ziprasidone 53 pregabalin 53 BPH symptoms 53 parkinsonism 53 rheumatoid arthritis RA 53 anticholinergics 53 6R BH4 53 rheumatic disease 53 placebo controlled studies 53 depressive episodes 53 anticholinergic 53 nasal allergies 53 triptan 53 amnestic mild cognitive impairment 53 sleepiness 53 nocturia 53 T2DM 53 RSV infection 53 INVEGA 53 opioid induced constipation 53 restorative sleep 53 Sjogren syndrome 53 orthostatic hypotension 53 Phenoptin 53 Laquinimod 53 adrenal insufficiency 53 chronic idiopathic constipation 53 claudication 53 refractory epilepsy 53 secondary efficacy endpoints 52 anticonvulsant 52 phase IIa